Announcement of Resolutions of the 19th Meeting of the Ninth Board of Directors of Tasly
Stock code: 600535 Stock abbreviation: Tasly Announcement number: Lin 2026-009
Tasly Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 19th Meeting of the Ninth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The notice of the 19th meeting of the ninth board of directors of Tasly Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") was issued in writing on March 20, 2026. The meeting was held by communication on March 23, 2026. 15 directors were expected to attend the meeting, but 15 actually attended. The meeting complied with the relevant provisions of the Company Law and the Articles of Association, and was legal and valid. After deliberation item by item, the following proposals were adopted:
1. Proposal on the Company’s Guarantee Estimates for 2026
The guaranteed parties are all wholly-owned subsidiaries/grandsons of the company. This guarantee plan is to meet the production and operation needs of Tianjin Tasly Pharmaceutical Commercial Co., Ltd. and Jiangsu Hongtai Pharmaceutical Co., Ltd. in 2026, which is conducive to improving financing efficiency and reducing financing costs. Based on the operating conditions, credit status and financial status of the relevant companies, the company's board of directors believes that the overall guarantee risk is controllable and that the guarantee will not harm the company's interests. The board of directors agreed to this guarantee and agreed to submit the proposal to the company's shareholders' meeting for review.
For details, please refer to the "Announcement on the Company's Guarantee Estimation for 2026" (Announcement No. Lin 2026-010) published by the company on the Shanghai Stock Exchange website (www.sse.com.cn).
The voting results were: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
2. Notice on Convening the 2025 Annual Shareholders Meeting
For details, please refer to the "Notice on Convening the 2025 Annual Shareholders Meeting" issued by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) (Announcement No.: Lin 2026-011).
The voting situation is: 15 valid votes, including: 15 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Tasly Pharmaceutical Group Co., Ltd. Board of Directors
March 24, 2026